Evaluation of Mandoorathy Mathirai (MM) for Jaundice

Preclinical and clinical evaluation of Mandoorathy Mathirai for the management of Hepatitis - An Open Labelled Phase-II Trial - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/05/087611

Enrollment

Registered

2025-05-26

Start date

Unknown

Completion date

Unknown

Last updated

2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K77- Liver disorders in diseases classified elsewhere

Interventions

Intervention1: Mandoorathy Mathirai (MM): Mandoorathy Mathirai (MM) 1 Tab (130 mg) Twice a day for 20 days Control Intervention1: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: Subjects diagnosed with Alcoholic liver diseases, Non Alcoholic liver diseases and Viral hepatitis

Exclusion criteria

Exclusion criteria: Galactosemia, Cholestasis. Pregnant and lactating women and those planning for pregnancy. Known cardiac diseases and other major illnesses.

Design outcomes

Primary

Measure	Time frame
To determine the efficacy of Mandoorathy Mathirai (MM) through percentage redution of liver Function test from base line to end of the treatment in patients with Alcoholic liver diseases, Non Alcoholic liver diseases and Viral hepatitis. Percentage reduction of LFT values from baseline to end of treatment (21 days)Timepoint: 20 days	—

Secondary

Measure	Time frame
- Changes in the Laboratory Parameters. - Assessment of Clinical improvements. - Monitoring Gamma GT and Renal Function Tests Timepoint: 0-21 days	—

Countries

India

Contacts

Public ContactDr B Manikandan

The Tamilnadu Dr M G R Medical University

sekarnis78@gmail.com9962536907

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026